Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 230

1.

Duration of a "Brown-Like" Phenotype of White Adipose Tissue Induced by the β3 Agonist CL-316,243.

Danysz W, Jinlai K, Li F.

Drug Res (Stuttg). 2019 May;69(5):265-270. doi: 10.1055/a-0667-8744. Epub 2018 Sep 6.

PMID:
30189459
2.

Rescue of Fmr1KO phenotypes with mGluR5 inhibitors: MRZ-8456 versus AFQ-056.

Westmark PR, Dekundy A, Gravius A, Danysz W, Westmark CJ.

Neurobiol Dis. 2018 Nov;119:190-198. doi: 10.1016/j.nbd.2018.08.008. Epub 2018 Aug 17.

PMID:
30125640
3.

Browning of white adipose tissue induced by the ß3 agonist CL-316,243 after local and systemic treatment - PK-PD relationship.

Danysz W, Han Y, Li F, Nicoll J, Buch P, Hengl T, Ruitenberg M, Parsons C.

Biochim Biophys Acta Mol Basis Dis. 2018 Sep;1864(9 Pt B):2972-2982. doi: 10.1016/j.bbadis.2018.06.007. Epub 2018 Jun 12.

4.

Effects of the Positive Allosteric Modulator of Metabotropic Glutamate Receptor 5, VU-29, on Impairment of Novel Object Recognition Induced by Acute Ethanol and Ethanol Withdrawal in Rats.

Marszalek-Grabska M, Gibula-Bruzda E, Bodzon-Kulakowska A, Suder P, Gawel K, Filarowska J, Listos J, Danysz W, Kotlinska JH.

Neurotox Res. 2018 Apr;33(3):607-620. doi: 10.1007/s12640-017-9857-z. Epub 2018 Jan 2.

5.

ADX-47273, a mGlu5 receptor positive allosteric modulator, attenuates deficits in cognitive flexibility induced by withdrawal from 'binge-like' ethanol exposure in rats.

Marszalek-Grabska M, Gibula-Bruzda E, Bodzon-Kulakowska A, Suder P, Gawel K, Talarek S, Listos J, Kedzierska E, Danysz W, Kotlinska JH.

Behav Brain Res. 2018 Feb 15;338:9-16. doi: 10.1016/j.bbr.2017.10.007. Epub 2017 Oct 10.

PMID:
29030082
6.

Further pharmacological characterization of eltoprazine: focus on its anxiolytic, anorexic, and adverse‑effect potential.

Gravius A, Dekundy A, Vanaga A, Franke L, Danysz W.

Acta Neurobiol Exp (Wars). 2017;77(1):77-85.

7.

mGlu1 receptor as a drug target for treatment of substance use disorders: time to gather stones together?

Dravolina OA, Zvartau E, Danysz W, Bespalov AY.

Psychopharmacology (Berl). 2017 May;234(9-10):1333-1345. doi: 10.1007/s00213-017-4581-1. Epub 2017 Mar 11. Review.

PMID:
28285325
8.

Optical isomers of phenibut inhibit [H(3)]-Gabapentin binding in vitro and show activity in animal models of chronic pain.

Belozertseva I, Nagel J, Valastro B, Franke L, Danysz W.

Pharmacol Rep. 2016 Jun;68(3):550-4. doi: 10.1016/j.pharep.2015.12.004. Epub 2015 Dec 22.

PMID:
26894962
9.

Effects of mGluR5 positive and negative allosteric modulators on brain damage evoked by hypoxia-ischemia in neonatal rats.

Makarewicz D, Słomka M, Danysz W, Łazarewicz JW.

Folia Neuropathol. 2015;53(4):301-8.

10.

Brain concentrations of mGluR5 negative allosteric modulator MTEP in relation to receptor occupancy--Comparison to MPEP.

Nagel J, Greco S, Parsons CG, Flik G, Tober C, Klein KU, Danysz W.

Pharmacol Rep. 2015 Jun;67(3):624-30. doi: 10.1016/j.pharep.2015.01.004. Epub 2015 Jan 22.

PMID:
25933979
11.

Effects of sarizotan in animal models of ADHD: challenging pharmacokinetic-pharmacodynamic relationships.

Danysz W, Flik G, McCreary A, Tober C, Dimpfel W, Bizot JC, Kostrzewa R, Brown RW, Jatzke CC, Greco S, Jenssen AK, Parsons CG.

J Neural Transm (Vienna). 2015 Sep;122(9):1221-38. doi: 10.1007/s00702-015-1392-6. Epub 2015 Mar 22.

PMID:
25796190
12.

Effects of dopamine uptake inhibitor MRZ-9547 in animal models of Parkinson's disease.

Dekundy A, Mela F, Hofmann M, Danysz W.

J Neural Transm (Vienna). 2015 Jun;122(6):809-18. doi: 10.1007/s00702-014-1326-8. Epub 2014 Oct 16.

PMID:
25319446
13.

Effect of the Aβ aggregation modulator MRZ-99030 on retinal damage in an animal model of glaucoma.

Salt TE, Nizari S, Cordeiro MF, Russ H, Danysz W.

Neurotox Res. 2014 Nov;26(4):440-6. doi: 10.1007/s12640-014-9488-6. Epub 2014 Aug 9.

PMID:
25106883
14.

The dopamine reuptake inhibitor MRZ-9547 increases progressive ratio responding in rats.

Sommer S, Danysz W, Russ H, Valastro B, Flik G, Hauber W.

Int J Neuropsychopharmacol. 2014 Dec;17(12):2045-56. doi: 10.1017/S1461145714000996. Epub 2014 Jun 25.

15.

Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease.

Parsons CG, Danysz W, Dekundy A, Pulte I.

Neurotox Res. 2013 Oct;24(3):358-69. doi: 10.1007/s12640-013-9398-z. Epub 2013 May 9. Review.

16.

Microdialysate analysis of monoamine neurotransmitters--a versatile and sensitive LC-MS/MS method.

Greco S, Danysz W, Zivkovic A, Gross R, Stark H.

Anal Chim Acta. 2013 Apr 10;771:65-72. doi: 10.1016/j.aca.2013.02.004. Epub 2013 Feb 14.

PMID:
23522114
17.

Using cholinergic M1 receptor positive allosteric modulators to improve memory via enhancement of brain cholinergic communication.

Chambon C, Jatzke C, Wegener N, Gravius A, Danysz W.

Eur J Pharmacol. 2012 Dec 15;697(1-3):73-80. doi: 10.1016/j.ejphar.2012.10.011. Epub 2012 Oct 17.

PMID:
23085025
18.

Assessment of the effects of NS11394 and L-838417, α2/3 subunit-selective GABA(A) [corrected] receptor-positive allosteric modulators, in tests for pain, anxiety, memory and motor function.

Hofmann M, Kordás KS, Gravius A, Bölcskei K, Parsons CG, Dekundy A, Danysz W, Dézsi L, Wittko-Schneider IM, Sághy K, Gyertyán I, Horváth C.

Behav Pharmacol. 2012 Dec;23(8):790-801. doi: 10.1097/FBP.0b013e32835a7c7e. Erratum in: Behav Pharmacol. 2013 Apr;24(2):153.

PMID:
23075708
19.

Effect of 5-HT5A antagonists in animal models of schizophrenia, anxiety and depression.

Kassai F, Schlumberger C, Kedves R, Pietraszek M, Jatzke C, Lendvai B, Gyertyán I, Danysz W.

Behav Pharmacol. 2012 Aug;23(4):397-406. doi: 10.1097/FBP.0b013e3283565248.

PMID:
22785385
20.

Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections.

Danysz W, Parsons CG.

Br J Pharmacol. 2012 Sep;167(2):324-52. doi: 10.1111/j.1476-5381.2012.02057.x. Review.

21.

The role of group I mGlu receptors in the expression of ethanol-induced conditioned place preference and ethanol withdrawal seizures in rats.

Kotlinska JH, Bochenski M, Danysz W.

Eur J Pharmacol. 2011 Nov 16;670(1):154-61. doi: 10.1016/j.ejphar.2011.09.025. Epub 2011 Sep 21.

PMID:
21946112
22.

Behavioural and cellular effects of exogenous amyloid-β peptides in rodents.

Chambon C, Wegener N, Gravius A, Danysz W.

Behav Brain Res. 2011 Dec 1;225(2):623-41. doi: 10.1016/j.bbr.2011.08.024. Epub 2011 Aug 22. Review.

PMID:
21884730
23.

Evaluation of brain pharmacokinetics of (+)MK-801 in relation to behaviour.

Wegener N, Nagel J, Gross R, Chambon C, Greco S, Pietraszek M, Gravius A, Danysz W.

Neurosci Lett. 2011 Sep 26;503(1):68-72. doi: 10.1016/j.neulet.2011.08.012. Epub 2011 Aug 17.

PMID:
21871531
24.

A new automated method to assess the rat recognition memory: validation of the method.

Chambon C, Wegener N, Gravius A, Danysz W.

Behav Brain Res. 2011 Sep 12;222(1):151-7. doi: 10.1016/j.bbr.2011.03.032. Epub 2011 Mar 21.

PMID:
21421012
25.

Effects of 5-HT6 antagonists, Ro-4368554 and SB-258585, in tests used for the detection of cognitive enhancement and antipsychotic-like activity.

Gravius A, Laszy J, Pietraszek M, Sághy K, Nagel J, Chambon C, Wegener N, Valastro B, Danysz W, Gyertyán I.

Behav Pharmacol. 2011 Apr;22(2):122-35. doi: 10.1097/FBP.0b013e328343d804.

PMID:
21301322
26.

Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia.

Dekundy A, Gravius A, Hechenberger M, Pietraszek M, Nagel J, Tober C, van der Elst M, Mela F, Parsons CG, Danysz W.

J Neural Transm (Vienna). 2011 Dec;118(12):1703-16. doi: 10.1007/s00702-010-0526-0. Epub 2010 Dec 16.

PMID:
21161716
27.

Interaction of blockers of ionotropic NMDA receptors and metabotropic glutamate receptors in a working memory test in rats.

Novitskaya YA, Dravolina OA, Zvartau EE, Danysz W, Bespalov AY.

Neurosci Behav Physiol. 2010 Sep;40(7):807-11. doi: 10.1007/s11055-010-9330-4. Epub 2010 Jul 17.

PMID:
20635207
28.

A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys.

Rylander D, Iderberg H, Li Q, Dekundy A, Zhang J, Li H, Baishen R, Danysz W, Bezard E, Cenci MA.

Neurobiol Dis. 2010 Sep;39(3):352-61. doi: 10.1016/j.nbd.2010.05.001. Epub 2010 May 7.

PMID:
20452425
29.

Metabotropic glutamate receptors as therapeutic targets for cognitive disorders.

Gravius A, Pietraszek M, Dekundy A, Danysz W.

Curr Top Med Chem. 2010;10(2):187-206. Review.

PMID:
20170472
30.

Effects of a positive allosteric modulator of mGluR5 ADX47273 on conditioned avoidance response and PCP-induced hyperlocomotion in the rat as models for schizophrenia.

Schlumberger C, Pietraszek M, Gravius A, Danysz W.

Pharmacol Biochem Behav. 2010 Mar;95(1):23-30. doi: 10.1016/j.pbb.2009.12.002. Epub 2009 Dec 5.

PMID:
19995568
31.

[Effects of NMDA and metabotropic glutamate receptors antagonists in working memory task in rats].

Novitskaia IuA, Dravolina OA, Zvartau EE, Danysz W, Bespalov AIu.

Zh Vyssh Nerv Deiat Im I P Pavlova. 2009 Jul-Aug;59(4):446-52. Russian.

PMID:
19795807
32.

Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity.

Schlumberger C, Pietraszek M, Gravius A, Klein KU, Greco S, Morè L, Danysz W.

Eur J Pharmacol. 2009 Nov 25;623(1-3):73-83. doi: 10.1016/j.ejphar.2009.09.006. Epub 2009 Sep 16.

PMID:
19765575
33.

Effects of glutamate and alpha2-noradrenergic receptor antagonists on the development of neurotoxicity produced by chronic rotenone in rats.

Alam M, Danysz W, Schmidt WJ, Dekundy A.

Toxicol Appl Pharmacol. 2009 Oct 15;240(2):198-207. doi: 10.1016/j.taap.2009.07.010. Epub 2009 Jul 17.

PMID:
19616571
34.

The anxiolytic and analgesic properties of fenobam, a potent mGlu5 receptor antagonist, in relation to the impairment of learning.

Jacob W, Gravius A, Pietraszek M, Nagel J, Belozertseva I, Shekunova E, Malyshkin A, Greco S, Barberi C, Danysz W.

Neuropharmacology. 2009 Aug;57(2):97-108. doi: 10.1016/j.neuropharm.2009.04.011. Epub 2009 May 6.

PMID:
19426746
35.

Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling.

Rylander D, Recchia A, Mela F, Dekundy A, Danysz W, Cenci MA.

J Pharmacol Exp Ther. 2009 Jul;330(1):227-35. doi: 10.1124/jpet.108.150425. Epub 2009 Apr 8.

36.

Pharmacodynamics of memantine: an update.

Rammes G, Danysz W, Parsons CG.

Curr Neuropharmacol. 2008 Mar;6(1):55-78. doi: 10.2174/157015908783769671.

37.

Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition.

Schlumberger C, Schäfer D, Barberi C, Morè L, Nagel J, Pietraszek M, Schmidt WJ, Danysz W.

Behav Pharmacol. 2009 Feb;20(1):56-66. doi: 10.1097/FBP.0b013e3283242f57.

PMID:
19179851
38.

Therapeutically relevant plasma concentrations of memantine produce significant L-N-methyl-D-aspartate receptor occupation and do not impair learning in rats.

Morè L, Gravius A, Nagel J, Valastro B, Greco S, Danysz W.

Behav Pharmacol. 2008 Oct;19(7):724-34. doi: 10.1097/FBP.0b013e3283123cad.

PMID:
18797249
39.

Oral creatine supplementation attenuates L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.

Valastro B, Dekundy A, Danysz W, Quack G.

Behav Brain Res. 2009 Jan 30;197(1):90-6. doi: 10.1016/j.bbr.2008.08.004. Epub 2008 Aug 12.

PMID:
18762218
40.

Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats.

Gravius A, Dekundy A, Nagel J, Morè L, Pietraszek M, Danysz W.

J Neural Transm (Vienna). 2008 Dec;115(12):1609-19. doi: 10.1007/s00702-008-0098-4. Epub 2008 Aug 9.

PMID:
18690408
41.

Antagonism of glutamatergic NMDA and mGluR5 receptors decreases consumption of food in baboon model of binge-eating disorder.

Bisaga A, Danysz W, Foltin RW.

Eur Neuropsychopharmacol. 2008 Nov;18(11):794-802. doi: 10.1016/j.euroneuro.2008.05.004. Epub 2008 Jun 24.

42.

A novel procedure for assessing the effects of drugs on satiation in baboons: effects of memantine and dexfenfluramine.

Foltin RW, Danysz W, Bisaga A.

Psychopharmacology (Berl). 2008 Sep;199(4):583-92. doi: 10.1007/s00213-008-1178-8. Epub 2008 May 15.

43.

Behavioral characterization of GLT1 (+/-) mice as a model of mild glutamatergic hyperfunction.

Kiryk A, Aida T, Tanaka K, Banerjee P, Wilczynski GM, Meyza K, Knapska E, Filipkowski RK, Kaczmarek L, Danysz W.

Neurotox Res. 2008 Jan;13(1):19-30.

PMID:
18367437
44.

Interactions of MRZ 2/576 with felbamate, lamotrigine, oxcarbazepine and topiramate in the mouse maximal electroshock-induced seizure model.

Luszczki JJ, Danysz W, Czuczwar SJ.

Pharmacology. 2008;81(3):259-65. doi: 10.1159/000114870. Epub 2008 Feb 4.

PMID:
18253065
45.

Effects of mGlu1 receptor blockade on working memory, time estimation, and impulsivity in rats.

Sukhotina IA, Dravolina OA, Novitskaya Y, Zvartau EE, Danysz W, Bespalov AY.

Psychopharmacology (Berl). 2008 Feb;196(2):211-20. Epub 2007 Oct 2.

PMID:
17909752
46.
47.

Comparison of the mGluR1 antagonist A-841720 in rat models of pain and cognition.

Morè L, Gravius A, Pietraszek M, Belozertseva I, Malyshkin A, Shekunova E, Barberi C, Schaefer D, Schmidt WJ, Danysz W.

Behav Pharmacol. 2007 Jul;18(4):273-81.

PMID:
17551319
48.

Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia.

Valastro B, Dekundy A, Krogh M, Lundblad M, James P, Danysz W, Quack G, Cenci MA.

J Neurochem. 2007 Aug;102(4):1395-409. Epub 2007 May 26.

49.
50.

Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model.

Dekundy A, Lundblad M, Danysz W, Cenci MA.

Behav Brain Res. 2007 Apr 16;179(1):76-89. Epub 2007 Jan 23.

PMID:
17306893

Supplemental Content

Loading ...
Support Center